Bristol-Myers hepatatis C therapy with Sovaldi meets study goals By: MarketWatch April 27, 2015 at 09:39 AM EDT Data showed 94% of patients that had hepatitis C following a transplant were cured after 12 weeks of treatment. Read More >> Related Stocks: AbbVie Bristol-Myers Squibb Gilead Sciences